CAMP4 Therapeutics (NASDAQ:CAMP) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

CAMP4 Therapeutics Corporation (NASDAQ:CAMPGet Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.32 and traded as high as $5.18. CAMP4 Therapeutics shares last traded at $4.90, with a volume of 128,474 shares trading hands.

Wall Street Analysts Forecast Growth

CAMP has been the topic of several research reports. Zacks Research lowered CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 15th. Chardan Capital set a $6.50 price objective on CAMP4 Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Piper Sandler reissued an “overweight” rating and set a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday. Weiss Ratings raised shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Finally, JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.56.

View Our Latest Stock Report on CAMP

CAMP4 Therapeutics Price Performance

The business has a 50 day moving average of $4.10 and a 200 day moving average of $4.32. The firm has a market capitalization of $307.48 million, a price-to-earnings ratio of -2.11 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMPGet Free Report) last released its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The company had revenue of $1.78 million during the quarter. As a group, equities analysts predict that CAMP4 Therapeutics Corporation will post -0.66 EPS for the current year.

Insider Buying and Selling at CAMP4 Therapeutics

In other news, Director Richard A. Young purchased 16,378 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average cost of $1.65 per share, for a total transaction of $27,023.70. Following the transaction, the director directly owned 186,388 shares of the company’s stock, valued at approximately $307,540.20. The trade was a 9.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. In the last 90 days, insiders have purchased 36,031 shares of company stock valued at $59,451. Company insiders own 21.69% of the company’s stock.

Institutional Investors Weigh In On CAMP4 Therapeutics

Several large investors have recently bought and sold shares of the company. Bridgeway Capital Management LLC acquired a new stake in CAMP4 Therapeutics in the second quarter worth $36,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of CAMP4 Therapeutics in the 4th quarter valued at $61,000. Jefferies Financial Group Inc. bought a new stake in shares of CAMP4 Therapeutics in the 4th quarter valued at $70,000. Bank of America Corp DE acquired a new stake in CAMP4 Therapeutics during the 2nd quarter worth $78,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in CAMP4 Therapeutics during the 4th quarter worth $115,000.

CAMP4 Therapeutics Company Profile

(Get Free Report)

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

Featured Stories

Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.